Jeffrey A. Meckler

CIK: 0001506916

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)6 (21.4%)

Position reduction

Option Exercises (M)4 (14.3%)

Derivative conversions

Awards (A)9 (32.1%)

Compensation grants

Other (G, F, J, C, D, …)9 (32.1%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

TVTX

Travere Therapeutics, Inc.

Director

INDP

Indaptus Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (28 total)

TVTX
Travere Therapeutics, Inc.
Sep 10, 2026
Exercise(M)
Direct
10K shares at avg. $17.44$174K
TVTX
Travere Therapeutics, Inc.
Sep 10, 2026
Exercise(M)
Direct
10K shares at avg. $26.52$265K
TVTX
Travere Therapeutics, Inc.
Sep 10, 2026
Sale(S)
Direct
1.7K shares at avg. $65.39$111K
TVTX
Travere Therapeutics, Inc.
Sep 10, 2026
Sale(S)
Direct
1.2K shares at avg. $66.15$79K
TVTX
Travere Therapeutics, Inc.
Sep 10, 2026
Sale(S)
Direct
14K shares at avg. $67.46$944K
TVTX
Travere Therapeutics, Inc.
Sep 10, 2026
Sale(S)
Direct
3.1K shares at avg. $68.09$211K
TVTX
Travere Therapeutics, Inc.
May 19, 2026
Award(A)
Direct
4K shares-
TVTX
Travere Therapeutics, Inc.
May 4, 2026
Exercise(M)
Direct
8K shares at avg. $16.33$131K
TVTX
Travere Therapeutics, Inc.
May 4, 2026
Sale(S)
Direct
8K shares at avg. $45.00$360K
INDP
Indaptus Therapeutics, Inc.
Feb 11, 2026
Disposition(D)
Warrants (right to buy)
Direct
1.5K shares-
INDP
Indaptus Therapeutics, Inc.
Feb 11, 2026
Award(A)
Warrants (right to buy)
Direct
12.1K shares-
INDP
Indaptus Therapeutics, Inc.
Feb 11, 2026
Disposition(D)
Warrants (right to buy)
Direct
12.1K shares-
INDP
Indaptus Therapeutics, Inc.
Feb 11, 2026
Award(A)
Warrants (right to buy)
Direct
1.5K shares-
INDP
Indaptus Therapeutics, Inc.
Feb 11, 2026
Disposition(D)
Warrants (right to buy)
Direct
3K shares-
INDP
Indaptus Therapeutics, Inc.
Feb 11, 2026
Award(A)
Warrants (right to buy)
Direct
3K shares-
INDP
Indaptus Therapeutics, Inc.
Dec 22, 2025
Award(A)
Direct
216.6K shares at avg. $2.03$440K
INDP
Indaptus Therapeutics, Inc.
Jul 27, 2025
Award(A)
Direct
6.1K shares at avg. $8.30$50K
TVTX
Travere Therapeutics, Inc.
May 15, 2025
Award(A)
Direct
6.5K shares-
INDP
Indaptus Therapeutics, Inc.
Apr 10, 2025
Disposition(D)
sStock Option (right to buy)
Direct
1.5K shares at avg. $0.04-
INDP
Indaptus Therapeutics, Inc.
Apr 10, 2025
Disposition(D)
Stock Option (right to buy)
Direct
1.6K shares at avg. $0.04-
INDP
Indaptus Therapeutics, Inc.
Apr 10, 2025
Disposition(D)
Stock Option (right to buy)
Direct
1.3K shares at avg. $0.04-
INDP
Indaptus Therapeutics, Inc.
Apr 10, 2025
Disposition(D)
Stock Option (right to buy)
Direct
4.8K shares at avg. $0.04-
INDP
Indaptus Therapeutics, Inc.
Apr 10, 2025
Disposition(D)
Stock Option (right to buy)
Direct
3.8K shares at avg. $0.04-
INDP
Indaptus Therapeutics, Inc.
Apr 10, 2025
Disposition(D)
Stock Option (right to buy)
Direct
813 shares at avg. $0.04-
INDP
Indaptus Therapeutics, Inc.
Nov 25, 2024
Award(A)
Direct
42.6K shares at avg. $1.18$50K

		Type	Shares	Price		Ownership
Sep 10, 2026	TVTX Travere Therapeutics, Inc.	Exercise(M)	10,000	$17.44	$174,400	Direct
Sep 10, 2026	TVTX Travere Therapeutics, Inc.	Exercise(M)	10,000	$26.52	$265,200	Direct
Sep 10, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	1,700	$65.39	$111,166	Direct
Sep 10, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	1,200	$66.15	$79,380	Direct
Sep 10, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	14,000	$67.46	$944,488	Direct
Sep 10, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	3,100	$68.09	$211,073	Direct
May 19, 2026	TVTX Travere Therapeutics, Inc.	Award(A)	4,000	-	$0	Direct
May 4, 2026	TVTX Travere Therapeutics, Inc.	Exercise(M)	8,000	$16.33	$130,640	Direct
May 4, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	8,000	$45.00	$360,000	Direct
Feb 11, 2026	INDP Indaptus Therapeutics, Inc.	Disposition(D) Warrants (right to buy)	1,519	-	-	Direct
Feb 11, 2026	INDP Indaptus Therapeutics, Inc.	Award(A) Warrants (right to buy)	12,136	-	-	Direct
Feb 11, 2026	INDP Indaptus Therapeutics, Inc.	Disposition(D) Warrants (right to buy)	12,136	-	-	Direct
Feb 11, 2026	INDP Indaptus Therapeutics, Inc.	Award(A) Warrants (right to buy)	1,519	-	-	Direct
Feb 11, 2026	INDP Indaptus Therapeutics, Inc.	Disposition(D) Warrants (right to buy)	3,033	-	-	Direct
Feb 11, 2026	INDP Indaptus Therapeutics, Inc.	Award(A) Warrants (right to buy)	3,033	-	-	Direct
Dec 22, 2025	INDP Indaptus Therapeutics, Inc.	Award(A)	216,617	$2.03	$439,733	Direct
Jul 27, 2025	INDP Indaptus Therapeutics, Inc.	Award(A)	6,068	$8.30	$50,379	Direct
May 15, 2025	TVTX Travere Therapeutics, Inc.	Award(A)	6,500	-	-	Direct
Apr 10, 2025	INDP Indaptus Therapeutics, Inc.	Disposition(D) sStock Option (right to buy)	1,500	$0.04	-	Direct
Apr 10, 2025	INDP Indaptus Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	1,563	$0.04	-	Direct
Apr 10, 2025	INDP Indaptus Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	1,250	$0.04	-	Direct
Apr 10, 2025	INDP Indaptus Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	4,750	$0.04	-	Direct
Apr 10, 2025	INDP Indaptus Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	3,750	$0.04	-	Direct
Apr 10, 2025	INDP Indaptus Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	813	$0.04	-	Direct
Nov 25, 2024	INDP Indaptus Therapeutics, Inc.	Award(A)	42,553	$1.18	$50,000	Direct

1-25 of 28 transactions

About Meckler Jeffrey A

Meckler Jeffrey A (SEC CIK 0001506916) files insider reports with the SEC as Director of Travere Therapeutics, Inc. (TVTX) and Co-Chief Executive Officer of Indaptus Therapeutics, Inc. (INDP).

Signal8 holds 11 ownership filings by Meckler Jeffrey A, all Form 4s, filed between Sep 30, 2024 and Sep 11, 2026. Those filings report 28 transactions, from Sep 30, 2024 to Sep 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Meckler Jeffrey A's filings is in SAN DIEGO, CA.

Recent filings by Meckler Jeffrey A

Sep 10, 2026: Option exercises of TVTX shares (2 lines, Form 4, code M).
Sep 10, 2026: Open-market sales of TVTX shares (4 lines, Form 4, code S).
May 19, 2026: Grant or award of TVTX shares (Form 4, code A).
May 4, 2026: Option exercise of TVTX shares (Form 4, code M).
May 4, 2026: Open-market sale of TVTX shares (Form 4, code S).

Other insiders filing for Travere Therapeutics, Inc. (TVTX)

Dube Eric M, CHIEF EXECUTIVE OFFICER
ROTE WILLIAM E., Chief Research Officer
Heerma Peter, EVP, CHIEF COMMERCIAL OFFICER
Inrig Jula, EVP, Head of R&D & CMO
REED ELIZABETH E, Chief Legal Officer and GC
Cline Christopher R., CHIEF FINANCIAL OFFICER

How to read Form 4 transaction codes